Proietti Ilaria, Skroza Nevena, Filippi Luca, Bernardini Nicoletta, Mambrin Alessandra, Tolino Ersilia, Rossi Giovanni, Marchesiello Anna, Marraffa Federica, Volpe Salvatore, Bagni Oreste, Potenza Concetta
Dermatology Unit "Daniele Innocenzi", "A. Fiorini" Hospital, Via Firenze, 1, 04019 Terracina, Italy.
Department of Nuclear Medicine, "Santa Maria Goretti" Hospital, Via Antonio Canova, 04100 Latina, Italy.
Life (Basel). 2021 Jul 14;11(7):692. doi: 10.3390/life11070692.
Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.
葡萄膜黑色素瘤(UM)是一种起源于虹膜、睫状体或脉络膜中黑色素细胞的眼部原发性肿瘤。它是最常见的眼内恶性肿瘤,常导致远处转移,对肝脏有特殊的趋向性。转移性UM预后较差,因为任何治疗都会影响这种致命疾病的自然病程。在此,我们报告一例54岁女性患者发生肝脏转移的UM病例,该患者最初接受纳武单抗治疗但未成功。随后患者在继续免疫治疗的同时安排接受选择性内照射治疗(SIRT)。这种联合治疗产生了完全且持久的反应,自肝转移诊断两年后,患者目前无疾病状态。SIRT与免疫治疗(IT)联合对于转移性UM具有非常有前景的前景,特别是考虑到传统化疗、单独IT治疗和靶向治疗令人失望或相互矛盾的结果。此外,这种联合治疗已显示出良好的安全性。然而,需要进一步研究以证实SIRT与IT联合的疗效,并澄清一些未解决的问题,例如这两种治疗的给药时机。